Company intelligence / Profile preview

HaLaCore Pharma

Sweden

Ownership: Private
Development stage: Other

Overview

HaLaCore Pharma developed a pipeline of novel preclinical AT2R agonists targeting fibrotic lung diseases. Its assets and technology were acquired by Vicore Pharma in November 2020 to enhance Vicore's preclinical and clinical-stage portfolio targeting diseases such as idiopathic pulmonary fibrosis. No clinical results published independently from HaLaCore Pharma; development continues under Vicore Pharma.

Therapeutic areas: Pulmonology
Modalities: Small molecule
Industry: Biotech

Partnerships

Emeriti Bio

Beyond the preview

Go deeper on HaLaCore Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HaLaCore Pharma.

Explore the full profile